Wiesbeck G A, Weijers H G, Chick J, Boening J
Alcohol Research Program, Psychiatric Clinic, University of Wuerzburg, Germany.
Alcohol Alcohol. 2000 Jul-Aug;35(4):384-9. doi: 10.1093/alcalc/35.4.384.
In an international double-blind placebo-controlled trial with 493 detoxified alcohol-dependent individuals, ritanserin, a specific 5-hydroxytryptamine, antagonist, was tested in three different dosages (2.5, 5, and 10 mg/day) against placebo over a period of 6 months. Data on changes in mood state, sleep quality, morning vigilance, clinical impression, and social functioning were analysed. None of the three dosages of ritanserin given revealed any significant effect against placebo on the above-mentioned parameters either at the end of treatment or upon relapse. Therefore, we conclude that patients suffering from alcohol dependence without concomitant psychiatric disorders do not benefit from additional treatment with (2.5, 5, or 10 mg/day) ritanserin.
在一项针对493名已戒酒的酒精依赖者的国际双盲安慰剂对照试验中，对一种特定的5-羟色胺拮抗剂利坦色林进行了三种不同剂量（2.5毫克/天、5毫克/天和10毫克/天）的测试，与安慰剂对照，为期6个月。分析了情绪状态、睡眠质量、早晨警觉性、临床印象和社会功能变化的数据。在治疗结束时或复发时，给予的三种利坦色林剂量在上述参数上均未显示出对安慰剂有任何显著效果。因此，我们得出结论，没有并发精神障碍的酒精依赖患者无法从额外服用（2.5毫克/天、5毫克/天或10毫克/天）利坦色林中获益。
